ReviewCancer metastasis reviews1992
Tissue factor as a tumor procoagulant.
Review in Cancer metastasis reviews, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 151 citations in OpenAlex.
- Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.Cancer metastasis reviews · 2024Review
- Venous thromboembolism and ovarian cancer risk: a Mendelian randomized study.Discover oncology · 2024Article
- A case of Trousseau syndrome: Screening, detection and complication.Open life sciences · 2024Article
- The ICU-venous thromboembolism score and tumor grade can predict inhospital venous thromboembolism occurrence in critical patients with tumors.World journal of surgical oncology · 2022Article
- Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study.JNCI cancer spectrum · 2021Article
- Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade.Pathology oncology research : POR · 2021Article
- Article
- Severe Fatal Systemic Embolism Due to Non-Bacterial Thrombotic Endocarditis as the Initial Manifestation of Gastric Adenocarcinoma: Case Report.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2018Article
- Deep vein thrombosis: pathogenesis, diagnosis, and medical management.Cardiovascular diagnosis and therapy · 2017Review
- Trousseau syndrome presenting with penile gangrene.JAAD case reports · 2017Article
- Impact of plasma fibrinogen levels in benign and malignant soft tissue tumors.Cancer biomarkers : section A of Disease markers · 2016Article
- The Role of Putative Phosphatidylserine-Interactive Residues of Tissue Factor on Its Coagulant Activity at the Cell Surface.PloS one · 2016Article
- Superior sagittal sinus thrombosis as the initial presentation of renal cell carcinoma.Proceedings (Baylor University. Medical Center) · 2015Article
- Postoperative Acute Pulmonary Embolism Following Pulmonary Resections.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2015Review
- Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin.Thrombosis research · 2014Article
- Cut-off value of D-dimer for prediction of deep venous thrombosis before treatment in ovarian cancer.Journal of gynecologic oncology · 2012Article
- Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.Thrombosis · 2011Article
- Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells.Journal of neuro-oncology · 2010Article
- Basic mechanisms and pathogenesis of venous thrombosis.Blood reviews · 2009Review
- Sharing tissue factor: a winning strategy in tumorigenesis.Arteriosclerosis, thrombosis, and vascular biology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Tissue factor is a cell surface glycoprotein responsible for initiating the extrinsic pathway of coagulation. Many tumor cell homogenates and intact tumor cells have been shown to contain tissue factor activity. Immunohistochemical studies show that many tumors associated with Trousseau's syndrome express tissue factor on their cell surfaces. Tumor cells shed membrane fragments which carry tissue factor that can account for the activation of the clotting system. Tumor cells also produce soluble substances that can induce tissue factor expression on host cells, such as endothelium and monocytes, at sites distant from the tumor. Although, all the functional TF molecules are localized on the outer cell membrane in many tumor cells, the procoagulant activity on the intact cell surface is largely dormant and can be greatly enhanced upon cell injury or damage. Tissue factor procoagulant activity on the cell surface can be modulated by alterations in the plasma membrane without loss of cell viability. Tissue factor activity on cell surfaces is largely regulated by a plasma inhibitor, tissue factor pathway inhibitor. This inhibitor binds to both functional and non-functional tissue factor/VIIa complexes on the cell surface and prevents non-functional tissue factor/VIIa complexes from becoming functional after cell injury or lysis. Heparin, but not warfarin, therapy is effective in preventing the occurrence of devastating thrombotic events in patients with Trousseau's syndrome and the reason(s) for this are still unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.